Which of the following drugs is preferred in kidney disease with microalbuminuria?

AIIMS M.Sc. Nsg Entrance exam-2026

Pharmacology

Medium

Appeared in: AIIMS M.Sc. Nsg Entrance exam-2026

Explanation

ACE inhibitors are the first-line treatment for patients with kidney disease and microalbuminuria due to their specific renoprotective (kidney-protective) properties.
They work by selectively dilating the efferent arterioles of the glomeruli, which are the blood vessels carrying blood away from the kidney's filters.
This action lowers the pressure inside the glomeruli (intraglomerular pressure), reducing the amount of albumin that is forced out and leaks into the urine.
This effect directly slows the progression of nephropathy, independent of the drug's effect on systemic blood pressure.

Option A: Loop diuretics (e.g., Furosemide) are primarily used to manage fluid overload and edema in patients with advanced kidney disease. They do not have a direct mechanism to reduce proteinuria.
Option B: Central vasodilators (e.g., Clonidine) are not first-line agents for hypertension and have no specific renoprotective effect to reduce microalbuminuria. They are typically reserved for resistant hypertension.
Option C: While Calcium Channel Blockers (CCBs) effectively lower blood pressure, they are less effective than ACE inhibitors at reducing proteinuria. They primarily dilate the afferent arteriole, which does not reduce intraglomerular pressure as effectively.

Visual 1: Diagram - A diagram of the kidney glomerulus, clearly labeling the afferent arteriole, efferent arteriole, and Bowman's capsule. An arrow should indicate that ACE inhibitors primarily cause vasodilation of the efferent arteriole, reducing pressure within the glomerulus.

Clinical Relevance

Nursing practice connection: Knowing Pharmacological management of kidney disease with microalbuminuria helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Early identification and management of microalbuminuria with an ACE inhibitor or ARB is a critical nursing responsibility to prevent or delay the progression to end-stage renal disease (ESRD) and reduce cardiovascular risk.
Nurses must monitor for side effects of ACE inhibitors, most notably a persistent dry cough, angioedema (a medical emergency), and hyperkalemia, especially in patients with reduced kidney function.
What if? If a patient on an ACE inhibitor develops an intractable dry cough, the nurse should anticipate the prescriber will discontinue the ACE inhibitor and switch the patient to an Angiotensin II Receptor Blocker (ARB), which has a similar renoprotective effect but a much lower incidence of cough.

How to Approach the Question

First, identify the core clinical problem in the question: a patient with both 'kidney disease' and 'microalbuminuria'.
Recognize that microalbuminuria is a key sign of early kidney damage and that the goal of treatment is not just to lower blood pressure, but to specifically protect the kidneys (renoprotection).
Recall the different classes of antihypertensive drugs and their primary mechanisms of action.
Differentiate the drug classes based on their specific effects on the kidney's glomerulus. Remember that ACE inhibitors have a unique effect on the efferent arteriole.
Select the drug class that is known to be first-line for its renoprotective effects in proteinuric kidney disease, which is ACE inhibitors.

Concept Tested & Keywords

Concept Tested: Pharmacological management of kidney disease with microalbuminuria.
Stem keywords: kidney disease, microalbuminuria, preferred drug
Lead-in keywords: preferred

QzJBdQ9dyIYmlnn-JtrzEj